The estimated Net Worth of James V Cassella is at least 3.61 百万$ dollars as of 15 February 2023. James Cassella owns over 3,762 units of Concert Pharmaceuticals Inc stock worth over 1,448,521$ and over the last 10 years he sold CNCE stock worth over 470,354$. In addition, he makes 1,695,040$ as Chief Development Officer at Concert Pharmaceuticals Inc.
James has made over 9 trades of the Concert Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,762 units of CNCE stock worth 31,375$ on 15 February 2023.
The largest trade he's ever made was selling 10,582 units of Concert Pharmaceuticals Inc stock on 17 April 2018 worth over 213,545$. On average, James trades about 1,793 units every 63 days since 2015. As of 15 February 2023 he still owns at least 173,061 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of James Cassella stock trades at the bottom of the page.
Dr. James V. Cassella Ph.D. serves as Chief Development Officer of the Company. He has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc., a biotechnology company, from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from 2004 to July 2012. From 1989 to 2004, Dr. Cassella held various management positions at Neurogen Corporation, a biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a B.A. in Psychology from the University of New Haven and a Ph.D. in Physiological Psychology from Dartmouth College and completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine.
As the Chief Development Officer of Concert Pharmaceuticals Inc, the total compensation of James Cassella at Concert Pharmaceuticals Inc is 1,695,040$. There are 3 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of 2,772,350$.
James Cassella is 65, he's been the Chief Development Officer of Concert Pharmaceuticals Inc since 2015. There are 3 older and 12 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
James's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over 69,766,120$ worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth 25,219,472$ . The most active insiders traders include Plc Gsk、Associates Gp Llcqvt Fund V...、Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of 447,820$. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth 50,380$.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: